Motif Bio PLC Filing of SEC Form F-3
14 Dicembre 2017 - 8:01AM
RNS Non-Regulatory
TIDMMTFB
Motif Bio PLC
14 December 2017
This announcement shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws or any such state or
jurisdiction.
Motif Bio plc
("Motif Bio" or the "Company")
Filing of SEC Form F-3
Motif Bio plc (AIM/NASDAQ: MTFB), a clinical stage
biopharmaceutical company specialising in developing novel
antibiotics, announces that it has filed a Form F-3 registration
statement with the United States Securities and Exchange Commission
("SEC"). This filing constitutes post-effective amendment No. 1 on
Form F-3 to the Company's registration statement on Form F-1, SEC
File No. 333-212491, which was the Company's registration statement
filed in conjunction with the NASDAQ IPO and originally declared
effective by the SEC on November 17, 2016 (the "Registration
Statement"). The post-effective amendment has been filed pursuant
to an undertaking in the Warrant Agent Agreement, dated November
23, 2016, between Motif Bio plc and The Bank of New York Mellon, as
warrant agent, to keep current the information contained in the
Registration Statement. The post-effective amendment specifically
concerns the exercise of the warrants issued in connection with the
Company's U.S. offering and European placement at the time of the
Company's NASDAQ IPO. The information included in this filing
updates and supplements the Registration Statement and the
prospectus contained therein. No additional securities are being
registered with respect to the post-effective amendment component
of this filing.
Additionally, the Form F-3 registration statement registers the
resale, from time to time, of up to 11,099,220 of the Company's
ordinary shares (including some represented by American depositary
shares) by certain selling shareholders named in the registration
statement, which ordinary shares are issuable to the selling
shareholders upon exercise of certain warrants that were previously
issued by the Company in connection with the Loan and Security
Agreement between Motif BioSciences Inc. and Hercules Capital, Inc.
and warrants issued in private placement transactions in 2015 and
2010. No additional securities are being issued by the Company
pursuant to this component of the filing.
Although the Form F-3 registration statement has been filed with
the SEC, it has not yet become effective.
For further information, please contact:
Motif Bio plc info@motifbio.com
Graham Lumsden (Chief Executive Officer)
Robert Dickey IV (Chief Financial Officer)
Walbrook PR Ltd. (UK FINANCIAL +44 (0) 20 7933 8780 / motifbio@walbrookpr.com
PR & IR)
Paul McManus Mob: +44 (0)7980 541
893
Mike Wort Mob: +44 (0)7900 608
002
MC Services AG (EUROPEAN IR) +49 (0)89 210 2280
Raimund Gabriel raimund.gabriel@mc-services.eu
The Trout Group (US IR) +1 (646 )378-2963
Meggie Purcell mpurcell@troutgroup.com
Lazar Partners (US PR) motiflp@lazarpartners.com
Chantal Beaudry +1 (646) 871-8480
Amy Wheeler +1 (646) 871-8486
About Motif Bio
Motif Bio plc (AIM/NASDAQ: MTFB) is a clinical-stage
biopharmaceutical company engaged in the research and development
of novel antibiotics designed to be effective against serious and
life-threatening infections in hospitalised patients caused by
multi-drug resistant bacteria, including MRSA. The Company's lead
product candidate, iclaprim, is being developed for high-risk MRSA
patient populations. The first proposed indication, and near-term
commercial opportunity, is for the treatment of acute bacterial
skin and skin structure infections (ABSSSI), one of the most common
bacterial infections, with 3.6 million patients hospitalised
annually in the US. The Company believes that iclaprim may be
suitable for first-line empiric therapy in ABSSSI patients,
especially those with renal impairment, with or without diabetes.
Unlike current standard of care antibiotics, in clinical trials to
date, nephrotoxicity has not been observed with iclaprim and dosage
adjustment has not been required in patients with renal
impairment.
Iclaprim has an underutilised mechanism of action compared to
other antibiotics. Clinical and microbiology data indicate iclaprim
has a targeted gram-positive spectrum of activity, low propensity
for resistance development, fixed dose administration and
favourable tolerability profile. Additionally, data support that
the inactive metabolites of iclaprim clear through the kidneys. The
Company also plans to develop iclaprim for hospital acquired
bacterial pneumonia (HABP), including ventilator associated
bacterial pneumonia (VABP), as there is a high unmet need for new
therapies in this indication. A Phase 2 trial was conducted to
study iclaprim in patients with HABP. Iclaprim has been studied in
an animal model of chronic pulmonary MRSA infection which mimics
the pathophysiology observed in patients with cystic fibrosis.
Results from this study were presented at IDWeek 2017(TM) on 6
October 2017 in San Diego, CA. Iclaprim has received Qualified
Infectious Disease Product (QIDP) designation from the FDA together
with Fast Track status. Upon acceptance by the FDA of a New Drug
Application (NDA), iclaprim will receive Priority Review status
and, if approved as a New Chemical Entity, will be eligible for 10
years of market exclusivity in the U.S. from the date of first
approval, under the Generating Antibiotic Incentives Now Act (the
GAIN Act). In Europe, 10 years of data exclusivity is
anticipated.
Forward-Looking Statements
This press release contains forward-looking statements. Words
such as "expect," "believe," "intend," "plan," "continue," "may,"
"will," "anticipate," and similar expressions are intended to
identify forward-looking statements. Forward-looking statements
involve known and unknown risks, uncertainties and other important
factors that may cause Motif Bio's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Motif Bio believes that these factors
include, but are not limited to, (i) the timing, progress and the
results of clinical trials for Motif Bio's product candidates, (ii)
the timing, scope or likelihood of regulatory filings and approvals
for Motif Bio's product candidates, (iii) Motif Bio's ability to
successfully commercialise its product candidates, (iv) Motif Bio's
ability to effectively market any product candidates that receive
regulatory approval, (v) Motif Bio's commercialisation, marketing
and manufacturing capabilities and strategy, (vi) Motif Bio's
expectation regarding the safety and efficacy of its product
candidates, (vii) the potential clinical utility and benefits of
Motif Bio's product candidates, (viii) Motif Bio's ability to
advance its product candidates through various stages of
development, especially through pivotal safety and efficacy trials,
(ix) Motif Bio's estimates regarding the potential market
opportunity for its product candidates, and (x) the factors
discussed in the section entitled "Risk Factors" in Motif Bio plc's
Annual Report on Form 20-F filed with the SEC on May 1, 2017, which
is available on the SEC's web site, www.sec.gov. Motif Bio plc
undertakes no obligation to update or revise any forward-looking
statements.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALXLLFDLFEFBV
(END) Dow Jones Newswires
December 14, 2017 02:01 ET (07:01 GMT)
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Lug 2023 a Lug 2024